Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (6140)	1/26/1999 11:21:00 PM
From: Triffin	Read Replies (2) \| Respond to of 56535

THREAD MINING...WLA/AGPH MORRIS PLAINS, N.J. (CBS.MW) --Warner-Lambert Co. agreed to buy Agouron Pharmaceuticals in a $2.1 billion deal giving it a developer of drugs that treat cancer, AIDS and other serious diseases. Under the pact, announced after the markets closed Tuesday, each share of Agouron stock will be exchanged for approximately $60 in Warner-Lambert (WLA) stock. Shares will exchanged in a range of 0.8108 to 0.93 shares of Warner-Lambert common stock for each share of Agouron (AGPH) common stock. The exchange ratio will be based on the average price of Warner-Lambert stock prior to the transaction's closing, the companies said. If they fail to complete their merger, Warner-Lambert has the option to purchase up to 19.9 percent of Agouron's common stock and has the right to a fee of at least $60 million. The purchase will allow Warner-Lambert to augment its new product pipeline and will significantly expand its presence in anti-viral and cancer treatments. In addition to gaining access to several promising late-stage compounds, Warner-Lambert gets Viracept, a leading HIV drug, immediately if the transaction is completed, Warner-Lambert said. "There's a strategic fit there," said Jay Silverman, an analyst at BancBoston Robertson Stephens in New York. While adding the deal was a bit of a surprise, Silverman pointed out that Warner-Lambert is developing its own AIDS drug and is building its line of cancer treatments. "There's been speculation since last summer that Agouron was on the block," though DuPont (DD), Pharmacia & Upjohn (PNU) and Abbott Labs (ABT) were seen as more likely suitors, the analyst said. The transaction will not require Warner-Lambert shareholder approval and is not expected to dilute future earnings. "In taking this action, we believe we have strategically enhanced our prospects for long-term growth without sacrificing our ability to meet expectations of superior near-term earnings performance," Melvin R. Goodes, Warner-Lambert chairman and chief executive officer, said in a statement. Shares of Agouron, based in La Jolla, Calif., rose 3 21/32 to 56 13/16 ahead of the announcement. Warner-Lambert, based in Morris Plains, N.J., makes products including Listerine, heartburn remedy Zantac 75 and Trident gum. Its Parke-Davis and Goedecke pharmaceuticals divisions make pain relievers, anesthetics, and diabetes and cholesterol treatments. Shares rose 1 5/8 to 69 1/8. Jim in CT..